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Abstract
Introduction: Intercellular adhesion molecule-1 (ICAM-1) is involved in migration and co-stimulation of T and B cells.
Membrane bound ICAM-1 is over expressed in the salivary glands (SG) of Sjo ¨gren’s syndrome (SS) patients and has therefore
been proposed as a potential therapeutic target. To test the utility of ICAM-1 as a therapeutic target, we used local gene
therapy in Non Obese Diabetic (NOD) mice to express soluble (s)ICAM-1 to compete with membrane bound ICAM-1 for
binding with its receptor. Therapy was given prior to and just after the influx of immune cells into the SG.
Methods: A recombinant serotype 2 adeno associated virus (rAAV2) encoding ICAM-1/Fc was constructed and its efficacy
tested in the female NOD mice after retrograde instillation in SG at eight (early treatment) and ten (late treatment) weeks of
age. SG inflammation was evaluated by focus score and immunohistochemical quantification of infiltrating cell types. Serum
and SG tissue were analyzed for immunoglobulins (Ig).
Results: Early treatment with ICAM-1/Fc resulted in decreased average number of inflammatory foci without changes in T
and B cell composition. In contrast, late treated mice did not show any change in focus scores, but immunohistochemical
staining showed an increase in the overall number of CD4+ and CD8+ T cells. Moreover, early treated mice showed
decreased IgM within the SGs, whereas late treated mice had increased IgM levels, and on average higher IgG and IgA.
Conclusions: Blocking the ICAM-1/LFA-1 interaction with sICAM-1/Fc may result in worsening of a SS like phenotype when
infiltrates have already formed within the SG. As a treatment for human SS, caution should be taken targeting the ICAM-1
axis since most patients are diagnosed when inflammation is clearly present within the SG.
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Introduction
Intercellular adhesion molecule-1 (ICAM-1) binds to lympho-
cyte function-associated antigen-1 (LFA-1) and macrophage 1
antigen (Mac-1) on immune cells, and is involved in adhesion and
migration of leucocytes in an inflammatory environment. ICAM-1
also plays an important role in the co-stimulatory pathway
involved in T cell activation and clonal expansion [1], and T cell
dependent B cell activation [2]. ICAM-1 is upregulated in
endothelial cells, lymphocytes, fibroblasts, and ductal epithelium
of salivary glands (SG) from Sjo ¨gren’s syndrome (SS) patients
[3,4,5,6]. SS is a systemic autoimmune disorder affecting secretory
tissue, including the lachrymal and salivary glands, resulting in
keratoconjunctivitis sicca and xerostomia. One of the pathological
hallmarks of the disease is the focal infiltration of mononuclear
cells into these secretory glands.
Currently, there is no effective treatment for SS. Since ICAM-1
is consistently found to be upregulated in SS, it has been suggested
that targeting ICAM-1 and the interaction with its ligands may
positively affect the disease outcome [7,8]. In previous studies,
blocking ICAM-1 interaction by systemic administration of
sICAM-1, has proven to be an effective therapy for autoimmune
diabetes in the Non Obese Diabetic (NOD) mouse. Intraperitoneal
(ip) injection with sICAM-1 before the clinical onset of disease in
NOD mice, resulted in decreased monocytic infiltration into the
pancreas, reduced Th1 cytokines levels and a lower diabetes
incidence [9]. Another study showed that treatment of NOD mice
with sICAM-1 after the onset of diabetes resulted in long-term
remission of diabetes in .50% of treated mice. Interestingly,
remission was not accompanied by decreased diabetogenic T cells
and did not result in overall immunosuppression, suggesting
induction of tolerance by sICAM-1 [10].
Independent of diabetes [11], the NOD mice also spontaneously
develop a complex of features that resembles SS in humans [11].
These mice spontaneously develop SG focal infiltrates, mainly
consisting of B and T cells, and within the inflamed SG,
membrane bound endothelial and epithelial ICAM-1 and LFA-1
are upregulated [12]. These characteristics make the NOD mouse
a reasonable model to study the potential therapeutic effect of
ICAM-1 interference on the development of SS.
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19962Since ICAM-1 plays a role in the migration of immune cells into
tissue, we tested the effect of sICAM-1 overexpression and
secretion by ductal cells in SG of NOD mice, before (early
treatment) and after (late treatment) the influx of inflammatory
cells, to see whether we can intervene with the formation of the
first focal infiltrates. The ductal cells are thought to play a crucial
role in the pathogenesis of SS [13] since focal infiltrates in SS are
mainly found surrounding the ductal epithelial cells. Moreover,
ductal cells produce high levels of pro-inflammatory cytokines and
can act as nonprofessional antigen presenting cells [14], making
these cells an attractive target. In this study, we investigated
whether sustained expression of sICAM-1 by ductal epithelial cells
via local gene therapy in the SG of NOD mice could affect the
development of SS-like clinical and immunological symptoms.
Results
Natural expression of ICAM-1 in the SGs
ICAM-1 expression was determined in the SGs of NOD mice
at the age of 8, 12, 16 and 20 weeks. Eight week old NOD mice
do not have focal infiltrates, but already expressed ICAM-1 in the
ductal and endothelial epithelium (Figure 1A). From 12 weeks to
20 weeks of age, when infiltrating lymphocytes are clearly
present, ICAM-1 was still expressed within the epithelial and
endothelial cells, but was also strongly expressed in the focal
infiltrates (Figure 1B–D). Quantification of ICAM-1 showed a
nearly 10-fold increase (p,0.005) of expression levels between 8
and 12 weeks of age, and stayed stable after 12 weeks (Figure 1E).
This increase was based on infiltrating cells, since increase in
expression of the ductal and endothelial cells did not change (data
not shown).
In vitro ICAM-1/Fc is secreted as a dimer and is
biologically active
ICAM-1/Fc was cloned into an AAV2 vector and the vector
was tested for protein expression after transfection of human
embryonic kidney (HEK 293) cells. Supernatant was harvested
48 hrs after transfection and a western blot was performed under
reducing and nonreducing conditions. ICAM-1/Fc secreted in the
supernatant migrated as expected as a dimer with a molecular
mass of approximately 240 kDa under nonreducing conditions
and as a monomer at 120 kDa under reducing conditions, similar
to commercially available recombinant ICAM-1/Fc (Figure 2A).
Supernatant was tested in an ELISA and 0.62 ug/ml of fusion
protein was detected, which was within the expected range for
AAV-plasmid expression (data not shown). An in vitro biological
activity assay showed a 52% binding of activated lymphocytes,
over expressing LFA-1, to wells coated with supernatant
containing ICAM-1/Fc, similarly to the commercially available
recombinant ICAM-1/Fc (Figure 2B).
Confirmation of local transgene delivery and stable
transduction of the SG in vivo after local administration
SGs of NOD mice of 8 or 10 weeks of age were cannulated with
AAV2-vectors containing ICAM-1/Fc or LacZ together with a
luciferase reporter vector. We used 1610
11 viral particles per SG
Figure 1. Natural ICAM-1 expression in NOD SGs. Frozen sections from 8 (N=5), 12 (N=5), 16 (N=4), and 20 (N=5) week old non-treated NOD
SGs were analyzed and quantified for natural ICAM-1 expression. Representative images (4006magnification) of ICAM-1 expression in NOD SGs are
shown at 8 (A), 12 (B), 16 (C), and 20 (D) weeks of age. Arrows indicate ICAM-1 expression at ductal and endothelial epithelium. E) Quantification of
ICAM-1 expression for all ages. Data shown are mean values +/2 SD. The P-value was determined by the parametric Student’s t-test.
doi:10.1371/journal.pone.0019962.g001
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dose for protein expression without causing a significant immune
response lies between 1610
10 and 1610
11 particles per gland
[15,16]. Prior to sacrifice, mice were anesthetized and were given
luciferin ip, after which luminescence was measured by an in vivo
luminescence imager (IVIS) to ensure localized transfer of the
vectors to the SGs. Figure 2C shows a representative mouse
expressing luciferase in the SG, 10 weeks after a single
administration. Vector delivery was also confirmed using
quantitative polymerase chain reaction (qPCR) on total DNA
extracted from treated SGs (data not shown). In agreement with
previous studies by our group expression was localized to the
salivary gland and not detected in other tissues of the animal
(data not shown).
Early treatment decreased overall inflammation of the
SGs
To determine the effect of treatment with ICAM-1/Fc on
inflammation of the SGs, NOD mice treated at 8 weeks (early
treatment) or at 10 weeks (late treatment) of age were euthanized at 20
weeks and the focus score (FS) was determined. FS in early ICAM-1/
Fc-treated mice were significantly lower compared with LacZ-treated
mice (2.360.9 versus 3.361.0, p,0.005). In contrast, late treatment
did not affect the FS (3.261.4 versus 3.061.1, p=0.78) (Figure 3).
Figure 2. In vitro and in vivo expression and biological activity of ICAM-1/Fc. A) In vitro expression of ICAM-1/Fc was shown using a reducing
and nonreducing SDS-PAGE gel. Under reducing conditions, ICAM-1/Fc migrated as a monomer with a molecular mass of approximately 120 kDa and
under nonreducing conditions as a dimer with a molecular mass of approximately 240 kDa. Lane 1 is recombinant ICAM-1/Fc and lane 2 is ICAM-1/Fc-
transfected supernatant. B) The biological activity of the ICAM-1/Fc was determined by adding stimulated and labeled T cell blastoma cells to plates
coated with ICAM-1/Fc-transfected supernatant. The optical density between before and after washing the wells is expressed as percentage binding
to LFA-1. Data shown are mean values +/2 SD of 3 experiments. PBS=phosphate buffered saline coated wells, mock=mock-transfected supernatant
coated cells. C) In vivo imaging of luciferase expression within the SGs. One representative mouse is shown.
doi:10.1371/journal.pone.0019962.g002
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cells in the SG
To identify the cell types affected by the ICAM-1/Fc treatment,
we performed immunohistochemistry (IHC) analysis and quanti-
fication of the foci of SG sections from early and late treated mice.
Despite the reduced number of foci, no specific cell type was found
to be reduced within these foci (Figure 4A). In contrast, late treated
mice showed a significant number of mice with an increased
relative integrated optical density (IOD) of positive CD4+
(p=0.03) and CD8+ T cell staining (p,0.01) (Figure 4A). No
differences in the relative IOD of macrophages (CD68), dendritic
cells (CD11c), B cells (B220+) and Treg (Foxp3+) were detected in
both early (p=0.97, p=0.99, p=0.40, and p=0.94 respectively)
and late (p=0.45, p=0.41, p=0.61, and p=0.78 respectively)
treated mice (Figure 4B–C).
ICAM-1/Fc can affect local and systemic immunoglobulin
levels and is disease stage dependent
ICAM-1 is involved in T cell activation and T cell dependent B
cell activation. Therefore, we studied whether interrupting the
ICAM-1/LFA-1 interaction would alter local and systemic
immunoglobulin (Ig) levels. Early treatment showed decreased
levels of IgM in the ICAM-1/Fc treated SGs compared to LacZ
controls (0.4260.13 mg/ml versus 0.5460.17 mg/ml, p=0.02);
IgG (p=0.47) and IgA (p=0.44) levels were unchanged
(Figure 5A). In contrast, late treatment with ICAM-1/Fc resulted
in increased levels of IgM (0.9360.35 mg/ml versus
0.6060.29 mg/ml, p=0.04) in the SGs, and tended to increase
local IgG (5.3661.47 mg/ml versus 3.9061.82 mg/ml, p=0.08)
and IgA levels (5.7862.34 mg/ml versus 3.8562.19 mg/ml,
p=0.08) (Figure 5B). Ig serum levels in the early treated mice
were unaltered (Figure 5C). In contrast, late ICAM-1/Fc treated
mice showed increased serum levels of IgM (0.5260.06 mg/ml
versus 0.3660.11 mg/ml, p,0.005), and IgA (0.7860.19 mg/ml
versus 0.5760.19, p=0.05), and tended to increase serum IgG
levels (1.7160.44 mg/ml versus 1.3460.51 mg/ml, p=0.19)
(Figure 5D).
Salivary flow was unaltered after ICAM-1/Fc delivery
NOD mice in our facility start to develop decreased salivary
flow from 16 weeks of age (Roescher et al, unpublished data). To
study whether the reduced SG inflammation after ICAM-1/Fc
treatment affected the salivary flow, we measured stimulated
salivary flow at the end of study (age 20 weeks). Despite the
observed reduction in focus score, stimulated salivary flow was not
improved in early treated mice. In addition, to make sure we did
not miss the window of effect of sICAM-1, we also tested early
treated mice at 16 weeks of age and also in this group no difference
in salivary flow was observed. The late treatment group also did
not show any difference in salivary flow compared with controls
despite the increase observed in SG infiltrating T cells (data not
shown).
Discussion
ICAM-1 is upregulated in many inflammatory diseases. It
functions as an adhesion molecule and plays a role in the
interaction and reciprocal activation of B and T cells by binding
to LFA-1 and Mac-1. Targeting the interaction between ICAM-1
and LFA-1 as a treatment for (auto)immunity has been the
subject in a number of studies (reviewed in [17]), and was shown
to have beneficial effects in animal models for autoimmune
diseases [9,10]. ICAM-1 and LFA-1 are upregulated in SG of SS
patients [3,4,5,6] suggesting an important role for these molecules
in this disease. This is further supported by the systemic
administration of antibodies to LFA-1 in NOD mice, which
resulted in inhibition of infiltration of the lachrymal glands [18].
Moreover, in vitro stimulation of human salivary gland (HSG)
ductal cells with interferon (IFN)-c gamma, a cytokine central to
SS [19], in the presence or absence of tumor necrosis factor
(TNF), increased the expression of ICAM-1 on the cell surface
[20]. It has therefore been speculated that interfering with the
ICAM-1/LFA-1 interaction may improve the clinical outcome in
SS. To study this, sICAM-1/Fc was expressed in the SG of NOD
mice in an initiation phase and in a more advanced stage of a SS-
like disease and the effect on inflammatory parameters was
analyzed.
NOD mice start to form SG infiltrates from 8 weeks of age. At
this age, prior to the development of infiltrates, mice clearly
expressed ICAM-1 in the ductal epithelium and endothelium.
Four weeks later the overall ICAM-1 expression was increased
10 fold, based on the expression of infiltrating cells. These data
confirm that endothelium and epithelium are already activated
prior the influx of lymphocytes and suggest that ICAM-1
signaling is important in an early phase of the pathogenesis of
SS in these mice. Based on these results and on existing
literature indicating that timing of ICAM-1 interference can
determine the outcome [21], we hypothesized that treatment
with ICAM-1/Fc at an initiation phase of the disease may differ
from and be more effective than treatment later in the disease
course. Therefore we treated 8 week old mice, just before
inflammatory cells are entering the SG, and at 10 weeks at an
accelerated phase of the disease when distinct foci have formed
in the majority of mice (N. Roescher et al, manuscript in
preparation).
Mice were cannulated with a non-replicating AAV type 2
vector, known to stably transduce ductal epithelial cells in the SG
[22]. Indeed, at the age of 20 weeks, vector DNA of ICAM-1/Fc
was still detected in the SG indicating stable transduction.
Figure 3. Decreased focus score in early treated mice. SGs from
early treated mice (N=16 for LacZ and N=19 for ICAM-1/Fc) and late
treated mice (N=8 for LacZ and N=9 for ICAM-1/Fc) were removed for
histologic analysis to assess the overall inflammation. Data are shown as
box and whisker plots with the mean and 5–95 percentile. The P-value
was determined by the parametric Student’s t-test. ET=early treatment,
LT=late treatment.
doi:10.1371/journal.pone.0019962.g003
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19962Moreover, in vivo imaging of luciferase activity, which was
cotransduced during administration of ICAM-1/Fc, showed
localized expression in the SG. No luciferase activity was detected
in the liver or in any other organ, indicating no systemic spread
(data not shown).
Inflammation of the SG was reduced in the early treated mice,
although no reduction of any specific cell type was found within
the foci, suggesting a general block on the influx of cells into the
SG. Interestingly, although the absolute FS was unchanged in the
late treatment group, the relative IOD of CD8+ cells and CD4+,
but not of Treg (Foxp3+) cells was increased compared with the
control mice. We also noted a ,2 fold increase in the average size
of the foci (data not shown), suggesting a specific recruitment to or
local expansion of effector T cells in the SG foci. These data is
consistent with previously reported T cell proliferation and IL-2
secretion after incubation with sICAM-1 in vitro, indicating direct
or indirect T cell activation by sICAM-1 [10]. In addition, the
contrasting effects observed in the different timing of treatment
indicate a shift in the role for therapeutic sICAM-1/Fc over the
course of disease progression. Although we did not study this in
detail, this notion is also supported by literature. Recently, anti-
ICAM-1 antibodies have been shown to positively affect the
clinical course of experimental autoimmune encephalitis (EAE)
when given in an early phase of the disease, whereas treatment
given in a later phase, worsened the clinical score of the treated
mice [21]. Based on these data and on the early expression of
endogenous ICAM-1 in the SG of mice, it would be interesting to
study sICAM-1/Fc delivery at an earlier age than 8 weeks.
However, the SG of NOD mice are not fully developed until the
age of 8 weeks and hence the orifices of the main ducts of the
submandibular gland draining into the oral cavity are very small
making it technically not feasible to cannulate the glands before
this age.
In parallel to our animal study, a clinical study was undertaken
at the National Institutes of Health (NIH) in patients with SS using
a monoclonal antibody to the CD11a subunit of LFA-1
(efalizumab), a ligand of ICAM-1. Unexpectedly, this treatment
increased inflammation in minor salivary glands and development
of de novo autoantibodies was detected in some patients [23].
Although this therapeutic approach is different from the approach
we present in this paper (e.g. the use of a monoclonal antibody
versus a soluble molecule), these results may further indicate that
blocking the ICAM-1/LFA-1 interaction may cause adverse
effects once inflammation is established.
Many SS patients have high levels of circulating immuno-
globulins, indicating B cell activation. Since ICAM-1 is involved
in T cell dependent B cell stimulation, directly or via the
production of IL-2 by activated T cells, we measured the effect of
sICAM-1 on local immunoglobulin production. Immunoglobulin
levels in the SG were differentially affected based on the timing
of sICAM-1/Fc expression, with the most striking differences
observed in IgM levels, suggesting again a dichotomous role for
sICAM-1 in the course of murine SS. Little is known about the
direct role of ICAM-1 on immunoglobulin synthesis, but the
effects observed could be the result of direct B cell stimulation
or indirect stimulation via activation of T cells by sICAM-1/
Fc. Additional research is required to elucidate the exact
mechanism.
Stimulated salivary flow was unchanged despite reduced
inflammation in the early treatment group, indicating that
infiltration of the SG by lymphocytes in the early treated group
was not sufficiently suppressed. On the other hand, salivary flow
was also unchanged in the late treatment group, despite the
increase of CD4+ and CD8+ T cells in the SG, suggesting that T
cells may not play a direct role in SG dysfunction of the inflamed
glands. Most importantly, these data imply that the loss of salivary
flow in SS is the end result of a complicated pathological process
that is poorly understood.
In summary, the expression of sICAM-1 in the SG of NOD
mice led to a modest decrease in autoimmune sialadenitis when
treatment was given at an early stage of the disease. However, late
treatment increased the number of CD4+ and CD8+ T cells in the
SG, and immunoglobulin levels in the SG and serum, indicating a
dichotomous role for sICAM-1 on the pathogenesis of murine SS
depending on disease stage. These data also indicate that caution
must be taken in treating human SS with therapies targeting the
ICAM-1/LFA-1 interaction, since it is likely that most patients are
diagnosed and request treatment in a more progressed stage of the
disease.
Materials and Methods
Vector design and in vitro expression
The plasmid for mouse ICAM-1 coupled to the Fc-part of
mouse immunoglobulin G1 (IgG1) was kindly provided by Dr.
Lemarchand (Universite ´ Rene ´ Descartes, France). We previously
reported the construction of recombinant (r)AAV-LacZ encoding
b-galactosidase [24]. The plasmid for rAAV-luciferase was a kind
gift of Dr. Mizukami (Jichi Medical School, Japan). Each gene was
cloned into an rAAV plasmid containing a cytomegalovirus
(CMV) promoter and the inverted terminal repeat (ITR)
sequences for AAV2.
The resulting plasmid (pAAV2-CMV-mICAM-1-mIgG1) was
transfected into HEK 293 cells and protein secretion into the
supernatant was quantified by an ELISA kit for mouse ICAM-1
(R&D systems, Minneapolis, MN). The size of the fusion protein
(ICAM-1/Fc) was confirmed by western blotting of the superna-
tant after transfection under reduced and nonreduced conditions
using a 10% SDS gel, rat anti-mouse ICAM-1 (R&D systems) as a
primary antibody and a labeled (IRDye 800 CW) goat anti-rat IgG
(Li-Cor, Lincoln, NE) as a secondary antibody. A recombinant
mouse ICAM-1/Fc chimera (R&D systems) was used as a positive
control.
In vitro biological activity
The biological activity of the expressed soluble ICAM-1/Fc was
tested in vitro for the ability to bind LFA-1. A flat bottom 96-well
plate was coated overnight (O/N) at 4uC with supernatant
containing ICAM-1/Fc or recombinant ICAM-1/Fc (R&D
systems) as positive control. Human T cell blastoma cells (HSB2,
ATCC, Manassas, VA) were stimulated with phorbol 12-myristate
13-acetate (PMA, Sigma-Aldrich, St. Louis, MO) at 50 nM final
concentration for 30 minutes (min) at 37uC to increase LFA-1
expression on the membrane. Cells were labeled with fluorescent
calcein-AM solution (Invitrogen, Carlsbad, CA) at 25 mM final
concentration for 30 min at 37uC. Stimulated and labeled HSB2
Figure 4. Increased relative IOD of CD4+ and CD8+ T cells in late treated mice. SGs from early and late treated mice with an average of 7
mice per group were quantified for CD4+ T cells, CD8+ T cells (A), CD68+ macrophages, CD11c+ dendritic cells (B), and B220+ B cells and Foxp3+
regulatory T cells (C). Data shown are the mean relative IOD. The P-value was determined by the parametric Student’s t-test or the non-parametric
Wilcoxon’s ranksum test depending on the Gaussian distribution for each staining.
doi:10.1371/journal.pone.0019962.g004
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4 cells/well) were incubated for 1.5 hr at 37uC in the
pre-coated wells. The plate was read before and after washing at
485–538 nm in a Spectramax M2 plate reader (Molecular Devices
Corporation, Sunnyvale, CA). The difference in optical density
between before and after washing was expressed as percentage
adhesion.
Figure 5. The timing of ICAM-1/Fc delivery affects local and systemic Ig levels. SG homogenates (A–B) and serum (C–D) from early
(average of N=8 per group) and late (average of N=18 per group) treated mice were analyzed for IgG, IgA and IgM. Data shown are mean +/2 SD.
The P-value was determined by the parametric Student’s t-test or the non-parametric Wilcoxon’s ranksum test depending on the Gaussian
distribution for each Ig.
doi:10.1371/journal.pone.0019962.g005
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NOD mice (001976 NOD/ShiLtJ, Jackson, Bar Harbor, ME)
were ordered at 6 weeks of age and were kept in pathogen-free
conditions. All procedures involving animals were performed in
compliance with the National Institutes of Health (NIH)
Guidelines on Use of Animals in Research. Animal protocols
were approved by the National Institute of Dental and
Craniofacial Research (NIDCR) Animal Care and Use Committee
(ACUC) and the NIH Biosafety Committee. The approval
identification number is 09-512.
In vivo vector delivery and detection
Prior to SG administration, all vectors were dialyzed for 3 hours
(hrs) against saline. Eight (early treatment) or ten (late treatment)
week old mice were anesthetized intramuscularly (im) with a
combination of ketamine (100 mg/mL, 1 mL/kg body weight;
Fort Dodge Animal Health, Fort Dodge, IA) and xylazine (20 mg/
mL, 0.7 mL/kg body weight; Phoenix Scientific, St. Joseph, MO).
To each submandibular gland 50 ml vector solution, containing
1610
11 vector (ICAM-1/Fc or control vector LacZ) particles plus
1610
9 luciferase reporter vector, was administered by retrograde
ductal instillation using a thin cannula (Intermedic PE10, Clay
Adams, Parsippany, NJ), as previously described [7]. This way of
administration is known to effectively and stably transduce the
epithelial ductal cells in the SG [15]. At the end of the treatment
(20 weeks of age), localization of vector delivery was confirmed by
luciferase activity after ip injection of 100 ml (40 mg/ml) luciferin
(Gold Biotechnology, St. Louis, MO) and luminescence was
imaged by an in vivo luminescence imager (Xenogen IVISH imager
using livingH image software, Alameda, CA). Vector DNA delivery
was also confirmed by homogenization of SG and total genomic
DNA was isolated using DNeasy blood & tissue kit (Qiagen, Venlo,
the Netherlands). The vector was detected using on an ABI
StepOnePlus Real-Time PCR system (Applied Biosystems,
Carlsbad, CA) using the following primers specific for the
therapeutic gene region: forward 59-TAGAATTCG-
CAATGGCTTCA-93, reverse 59-CTTCTCTGGGATGGATG-
GAT and probe 59-CACCAGGCCCAGGGATCACA-39.
Saliva collection and sacrifice
Mice were anesthetized as described above and saliva secretion
was induced by subcutaneous (sc) injection of pilocarpine (0.5 mg/
kg BW; Sigma-Aldrich, St. Louis, MO). Stimulated whole saliva
was collected for 20 minutes from the oral cavity with a
hematocrit tube (Drummond Scientific Company, Broomall, PA)
placed into a preweighed 0.5 ml microcentrifuge tube, and the
volume was determined gravimetrically. At time of sacrifice, serum
and the SGs were collected to analyze the effect of treatment
compared with the controls.
Histological assessment and immunohistochemistry
At the end of the study the mice were euthanized and one cross
sectional part of the SG was embedded in paraffin and sections
were cut at 5 mm. Three non-consecutive sections were stained
with hematoxylin and eosin (H&E). The FS was determined for
each mouse, in which one focus is defined as an aggregate of 50 or
more lymphocytes and the FS defined as the average foci per
4m m
2 SG tissue. Slides were scored blindly by at least 2 different
researchers. Other paraffin sections were stained with rat anti-
mouse B220 (kindly provided by Dr. K. van Gisbergen, University
of Amsterdam) after heat-induced citrate antigen-retrieval.
Another cross-sectional part of the SG was collected and frozen
into OCT compound (Tissue-Tek, Sakura, Zoeterwoude, the
Netherlands) and sections were cut at 5 mm. Sections were stained
with rat anti-mouse CD4 (eBioscience, San Diego, CA), rat anti-
mouse CD8 (eBioscience), rat anti-mouse CD68 (Abcam, Cam-
bridge, MA), and hamster anti-mouse CD11c (Abcam), each at a
1:100 dilution. Anti-Foxp3 (eBioscience) was used at a 1:50
dilution using an extra amplification step with biotin labeled
tyramide (PerkinElmer, Waltham, MA) and streptavidin labeled
HRP (PerkinElmer). Foxp3 is considered a reasonable marker for
the presence of Tregs in tissue.
For endogenous ICAM-1 expression, salivary glands of 8, 12, 16
and 20 week old non-treated were frozen in OCT compound,
sections were cut at 7 mm and were stained with rat anti-mouse
ICAM-1 (Abcam). As secondary antibodies goat anti-rat-HRP
(Southern Biotechnology, Birmingham, AL) and goat anti-
hamster-HRP (Jackson Immunoresearch, Suffolk, UK) were used.
Staining was developed with AEC substrate (Dako, Glostrup,
Denmark). Images of the high-power fields taken of the foci were
analyzed using the Qwin analysis system (Leica, Cambridge, UK),
as described previously [25]. Within each group of treated and
control mice, absolute staining intensity values were divided by the
average of controls and expressed as relative IOD. In addition, the
percentage of total SG tissue surface area taken up by foci was
quantified for each section.
Detection of IgA, IgG and IgM in serum and SGs
Serum was collected by heart puncture just after sacrifice, blood
was left to clot for 3 hrs on ice and was spun down for 25 minutes
at 2500 g at 4uC. SG homogenates were made by homogenizing a
part of the frozen SG in HEPES lysis buffer containing protease
inhibitors (Protease Mini, Roche, Indianapolis, IN) overnight at
4uC and total protein was determined with BCA
TM protein assay
kit (Pierce, Rockford, IL). IgA, IgG and IgM in serum and tissue
homogenates were determined using commercially available
ELISA kits (Bethyl Laboratories, Montgomery, TX) and final
concentrations were corrected for total protein concentration.
Statistical analysis
Differences between experimental groups in focus scores were
assessed using Student’s t-tests. Differences in all other experi-
ments were assessed using the non-parametric Wilcoxon’s
ranksum test or the parametric Student’s t-test depending on the
Gaussian distribution. All the analyses were performed with
GraphPad Prism statistical software (GraphPad Software Inc.
version 5.01, La Jolla, CA). A P value#0.05 was considered to be
statistically significant.
Author Contributions
Conceived and designed the experiments: NR JLV PPT JAC. Performed
the experiments: NR JLV HY. Analyzed the data: NR JLV JAC.
Contributed reagents/materials/analysis tools: GGI PPT JAC. Wrote the
paper: NR JLV HY GGI PPT JAC.
References
1. Deeths MJ, Mescher MF (1999) ICAM-1 and B7-1 provide similar but distinct
costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by
ICAM-1. Eur J Immunol 29: 45–53.
2. Poudrier J, Owens T (1994) CD54/intercellular adhesion molecule 1 and major
histocompatibility complex II signaling induces B cells to express interleukin 2
receptors and complements help provided through CD40 ligation. J Exp Med
179: 1417–1427.
3. Aziz KE, McCluskey PJ, Montanaro A, Wakefield D (1992) Vascular
endothelium and lymphocyte adhesion molecules in minor salivary glands of
patients with Sjogren’s syndrome. J Clin Lab Immunol 37: 39–49.
Effect of Soluble ICAM-1 in NOD Mice
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e199624. Kapsogeorgou EK, Dimitriou ID, Abu-Helu RF, Moutsopoulos HM,
Manoussakis MN (2001) Activation of epithelial and myoepithelial cells in the
salivary glands of patients with Sjogren’s syndrome: high expression of
intercellular adhesion molecule-1 (ICAM.1) in biopsy specimens and cultured
cells. Clin Exp Immunol 124: 126–133.
5. Chen WS, Lin KC, Chen CH, Liao HT, Wang HP, et al. (2009) Autoantibody
and biopsy grading are associated with expression of ICAM-1, MMP-3, and
TRAIL in salivary gland mononuclear cells of Chinese patients with Sjogren’s
syndrome. J Rheumatol 36: 989–996.
6. Turkcapar N, Sak SD, Saatci M, Duman M, Olmez U (2005) Vasculitis and
expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-
1, and E-selectin in salivary glands of patients with Sjogren’s syndrome.
J Rheumatol 32: 1063–1070.
7. Kok MR, Baum BJ, Tak PP, Pillemer SR (2003) Use of localised gene transfer to
develop new treatment strategies for the salivary component of Sjogren’s
syndrome. Ann Rheum Dis 62: 1038–1046.
8. Thanou-Stavraki A, James JA (2008) Primary Sjogren’s syndrome: current and
prospective therapies. Semin Arthritis Rheum 37: 273–292.
9. Martin S, Heidenthal E, Schulte B, Rothe H, Kolb H (1998) Soluble forms of
intercellular adhesion molecule-1 inhibit insulitis and onset of autoimmune
diabetes. Diabetologia 41: 1298–1303.
10. Bertry-Coussot L, Lucas B, Danel C, Halbwachs-Mecarelli L, Bach JF, et al.
(2002) Long-term reversal of established autoimmunity upon transient blockade
of the LFA-1/intercellular adhesion molecule-1 pathway. J Immunol 168:
3641–3648.
11. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG (2002) Two
NOD Idd-associated intervals contribute synergistically to the development of
autoimmune exocrinopathy (Sjogren’s syndrome) on a healthy murine
background. Arthritis Rheum 46: 1390–1398.
12. Faveeuw C, Gagnerault MC, Lepault F (1994) Expression of homing and
adhesion molecules in infiltrated islets of Langerhans and salivary glands of
nonobese diabetic mice. J Immunol 152: 5969–5978.
13. Moutsopoulos HM (1994) Sjogren’s syndrome: autoimmune epithelitis. Clin
Immunol Immunopathol 72: 162–165.
14. Tsunawaki S, Nakamura S, Ohyama Y, Sasaki M, Ikebe-Hiroki A, et al. (2002)
Possible function of salivary gland epithelial cells as nonprofessional antigen-
presenting cells in the development of Sjogren’s syndrome. J Rheumatol 29:
1884–1896.
15. Yamano S, Huang LY, Ding C, Chiorini JA, Goldsmith CM, et al. (2002)
Recombinant adeno-associated virus serotype 2 vectors mediate stable
interleukin 10 secretion from salivary glands into the bloodstream. Hum Gene
Ther 13: 287–298.
16. Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, et al. (2003) Local
adeno-associated virus-mediated interleukin 10 gene transfer has disease-
modifying effects in a murine model of Sjogren’s syndrome. Hum Gene Ther
14: 1605–1618.
17. Anderson ME, Siahaan TJ (2003) Targeting ICAM-1/LFA-1 interaction for
controlling autoimmune diseases: designing peptide and small molecule
inhibitors. Peptides 24: 487–501.
18. Mikulowska-Mennis A, Xu B, Berberian JM, Michie SA (2001) Lymphocyte
migration to inflamed lacrimal glands is mediated by vascular cell adhesion
molecule-1/alpha(4)beta(1) integrin, peripheral node addressin/l-selectin, and
lymphocyte function-associated antigen-1 adhesion pathways. Am J Pathol 159:
671–681.
19. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, et al. (2006)
Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target
organs of primary Sjogren’s syndrome. Proc Natl Acad Sci U S A 103:
2770–2775.
20. Wu AJ, Kurrasch RH, Katz J, Fox PC, Baum BJ, et al. (1994) Effect of tumor
necrosis factor-alpha and interferon-gamma on the growth of a human salivary
gland cell line. J Cell Physiol 161: 217–226.
21. Doerck S, Gobel K, Weise G, Schneider-Hohendorf T, Reinhardt M, et al.
Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of
inflammation in adoptive transfer model of multiple sclerosis. PLoS One 5:
e15478.
22. Voutetakis A, Kok MR, Zheng C, Bossis I, Wang J, et al. (2004) Reengineered
salivary glands are stable endogenous bioreactors for systemic gene therapeutics.
Proc Natl Acad Sci U S A 101: 3053–3058.
23. Nikolov NP, Nagaraju K, Ghimbovschi S, Alba M, Lapteva L, et al. (2009)
Blocking LFA-1 with Efalizumab Promotes Inflammation, T Cell Activation and
Autoimmunity in Primary Sjo ¨gren’s Syndrome. Arthritis Rheum 60: 499.
24. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA (2001) Adeno-
associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding
for hemagglutination and efficient transduction but differ in sialic acid linkage
specificity. J Virol 75: 6884–6893.
25. Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman AH, et al.
(2005) Reliability of computerized image analysis for the evaluation of serial
synovial biopsies in randomized controlled trials in rheumatoid arthritis.
Arthritis Res Ther 7: R862–867.
Effect of Soluble ICAM-1 in NOD Mice
PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e19962